“At Topadur Pharma AG, we are developing disruptive therapies for rare and aging diseases. Currently we are in the clinical phase for digital ulcers in systemic sclerosis patients. We are running a co-development initiative for alopecia treatment in Greater China and our collaboration with renowned academic institutions ensures that our research is grounded in cutting-edge science.”

PD Dr. Matthias Schäfer, Chief Innovation Officer